Sometimes the most informative information doesn't come from a pile of formal research, but "observational" evidence from credible sources.
Pre-ozempic, when only short acting GLPs were available, and only used to treat (rich) diabetics, after a while it was noticed this group of "sickly" diabetics were developing less disease and living longer than their non-diabetic counterparts.
So because of that, the growing mountain of evidence of other health benefits, and essentially no evidence of harms from long term use (yes, I know about the rare cases of pancreatitis and gastroparisis, but those are not really GLP induced), I'm a big proponent of everyone hitting those GLP and GIP receptors, needing weight loss or not.
Jury's still out on Glucagon, which is why I'm holding off on Reta, though it's probobly fine.